Latest: FDA Approves New Biosimilar for Oncology Treatment
Neurology

Donanemab Dosing and ARIA Risk in TRAILBLAZER-ALZ 6

by Neurology Live
0 Comments
0 Mins
Expert Stephen Salloway, MD, discussed findings from the TRAILBLAZER-ALZ 6 study, highlighting how a stepwise donanemab dosing regimen significantly lowered rates of ARIA in early Alzheimer disease. Supported by Eli Lilly.
Tags:
Neurology Live
Author

Neurology Live

Previous Post
In internal FDA town hall, employees raise concerns about staffing, impromptu expert meetings
Next Post
STAT+: Trump administration launches investigation into Harvard’s federally funded research patents
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago